Ping An CSI Medicine and Medical Device Innovation ETF

Optimization of Innovative Drug Medical Insurance Mechanism and Revival of Financing Drive Up Industry Sentiment

00945

159837

516820

516500

Manulife Singapore will launch the Shield™ multi-cancer detection test in May 2026 through its partnership with Guardant Health, becoming the first in Singapore to offer this blood test for multiple cancers. This initiative supports preventive healthcare, addressing the rising demand for early cancer detection. The Shield™ test has received Breakthrough Device Designation from the FDA and was recognized as Oncology Product Innovation of the Year. Manulife aims to empower customers in managing their health and finances.

Singapore Business Review

Guardant Health

MANULIFE-S

Manulife Financial

Ark Genomic Revolution ETF

E Fund CSI Biotechnology Theme ETF

Minsheng Royal CSI Biotechnology Theme ETF

VanEck Biotech ETF

ChinaAMC CSI Biotechnology Theme ETF

Hwabao WP CSI Medical Service ETF

Direxion S&P Biotech Bull 3X

China Merchants CSI Biotechnology Theme ETF

Direxion S&P Biotech Bear 3X

Manulife Singapore to offer multi-cancer blood test starting May

The National Kidney Foundation (NKF) has invested in Biohope, a biotechnology firm focused on personalized medicine for kidney transplantation. This investment aims to support Biohope's clinical validation studies and regulatory approval for its Immunobiogram® platform, which tailors immunosuppressive therapy to individual patients. The technology seeks to reduce complications and improve graft survival for kidney transplant recipients, addressing the urgent need for personalized post-transplant care. NKF's Innovation Fund, launched in 2021, supports innovative kidney therapies to enhance patient outcomes.

prnewswire

Health Care Select Sector SPDR

First Trust NYSE Arca Biotech Index Fd

iShares Global Healthcare

VG Health

Invesco Biotechnology & Genome ETF

Proshares UltraShort Nasdaq Biotech

SPDR S&P Biotech

iShares Biotechnology ETF

Proshares Ultra Nasdaq Biotech

Invesco Nasdaq Biotechnology ETF

iShares US Pharma

ALPS Medical Breakthrough

01:00 ETNational Kidney Foundation Innovation Fund Invests in Biohope to Advance Personalized Medicine in Kidney Transplantation

159892

159859

510660

588250

560600

588130

Ab&B Bio-Tech CO., LTD. has begun Phase I and II trials for its recombinant RSV vaccine after receiving approval from China's National Medical Products Administration. The vaccine targets respiratory syncytial virus, crucial for vulnerable populations in China. Despite promising preclinical results, trading of the company's shares remains suspended since April 1, 2026, and there is no guarantee the vaccine will reach the market. Ab&B Bio-Tech focuses on innovative vaccines and has a diverse pipeline, including influenza and rabies vaccines.

Tip Ranks

ChinaAMC Hang Seng Biotechnology Technology ETF(QDII)

Guotai CSI Bio-medicine ETF

Tianhong CNI BIOMEDICINE ETF

Bosera Hang Seng Health Care ETF(QDII)

GF CSI HK Innovative Drugs Industry ETF(QDII)

Hwabao WP Hang Seng SCHK Innovative Drug Select ETF

Fullgoal Hang Seng SCHK Innovative Drug & Healthcare ETF

ICBCCS SSE STAR Biology and Medicine ETF

Yinhua CSI Innovative Drugs Industry ETF

ChinaAMC SSE Health Care ETF Initiating Fund

Bosera Hang Seng SCHK Innovative Drug Select ETF

Penghua SSE STAR Biology and Medicine ETF

Huaan Hang Seng Biotech ETF

E Fund CSI 300 Health Care ETF

Founder Fubon CSI Medicine and Medical Device Innovation ETF

China Southern Hang Seng Biotech ETF(QDII)

ChinaAMC SSE STAR Biology and Medicine ETF

AB&B BIO-TECH-B

Ab&B Bio-Tech Starts Early-Stage Trials for High-Yield RSV Vaccine as Trading Remains Suspended

ZLAB

09688

159570

Hong Kong's innovative drug sector continues to experience a downturn, with Zai Labdropping over 6% and Jiangsu Hengrui Medicinefalling more than 4%. According to Jin10, other companies such as CSPC Pharmaceutical Groupand WuXi AppTecalso saw declines.

CoinLive

Zai Lab

ZAI LAB

China Universal CNI HK Connect Innovative Drugs Industry ETF

Huatai-PB Hang Seng Innovative Drugs Industry ETF(QDII)

China Universal 800 Health Care ETF

Guotai SSE STAR Brand Name Drug ETF

Hwabao WP CSI Pharmaceuticals ETF

E Fund Hang Seng SCHK Innovative Drug ETF

HENGRUI PHARMA

CSPC PHARMA

WUXI APPTEC

WuXi AppTec

STOCKS | Hong Kong's Innovative Drug Sector Declines

01177

G Sachs has raised the target price for SBP GROUPto HKD8.05, maintaining a Buy rating following the company's agreement with GlaxoSmithKline (GSK) for exclusive commercialization rights in China for the hepatitis B drug bepirovirsen. The drug, expected to be approved in 2027, aligns with the treatment needs of China's 75 million chronic hepatitis B patients. G Sachs has increased its earnings forecasts for 2027 and 2028 by 1.1% and 1.7%, respectively, reflecting the anticipated sales contribution from bepirovirsen.

AASTOCKS News

SBP GROUP

GlaxoSmithKline plc

Goldman Sachs

GS Hldg R

GSK plc Sponsored ADR

G Sachs Raises SBP GROUP  TP to HKD8.05, Maintains Buy on Introduction of GSK Hepatitis B Drug

02509

603259

WXXWY

JPMorgan's report highlights the National Healthcare Security Administration's new plan for the 2026 National Reimbursement Drug List, which allows drugs to apply for NRDL inclusion before formal approval. This change is expected to enhance the commercialization prospects for innovative drug developers in China. The report identifies INNOVENT BIO, WUXI APPTEC, WUXI XDC, and SKB BIO as top picks, benefiting from clearer pricing rules and faster market access for high-priced drugs.

QYUNS-B

WuXi Biologics

SKB BIO

WUXI BIO

TEDA BIOMEDICAL

INNOVENT BIO

WUXI XDC

Guotai CSI Hugangshen Innovative Drugs Industry ETF

Penghua CSI HK Connect Health Care Composite ETF

JPMorgan Chase

JPMORGAN CHASE & CO. 4.20% DEP SHS REPSTG 1/400TH PFD SER MM

JPMORGAN CHASE & CO. 6%NON CUM DEP SHS REP 1/400TH PFD SER EE

JPMORGAN CHASE & CO. DEP REP 1/400TH (5.75% NON CUM PFD DD)

JPMORGAN CHASE & CO. 4.625% DEP SH RE 1/400TH INT NO CU PF LL

JPMorgan Chase & Co.

JPMORGAN CHASE & CO. 4.55% DEP SHS REPSTG 1/400TH PFD SER JJ

JPMORGAN CHASE & CO. 4.75 DEP SHS REP 1/400 NCUM PFD SR GG

JPM: NRDL Adjustment to Accelerate Commercialization of Innovative Drugs; Top Picks INNOVENT BIO , WUXI APPTEC , WUXI XDC , SKB BIO

HBM Holdings Ltd. announced that its independent non-executive director, Dr. Xiaoping Ye, is under investigation by the China Securities Regulatory Commission for alleged information disclosure violations. The company stated that Dr. Ye does not engage in daily management and will cooperate with regulators. HBM's operations are reported to be normal, with no expected impact from the probe. Shareholders are advised to exercise caution during the inquiry. The latest analyst rating for HBM stock is a Buy, with a price target of HK$17.00.

HBM HOLDINGS-B

Tigermed

TIGERMED

HBM Holdings Says Director Probed by CSRC, Sees No Impact on Operations

02616

CStone Pharmaceuticals has launched nationwide supply of its domestically produced pralsetinib capsules in China, enhancing local supply chain for this cancer therapy. The drug's sales surged over 430% year-on-year, with expectations to exceed RMB 300 million in 2026. This move aims to meet rising clinical demand and improve cost efficiency. Pralsetinib is approved for RET fusion-positive non-small cell lung cancer and thyroid cancer, reinforcing CStone's position in precision oncology in the region.

CSTONE PHARMA-B

CStone Launches Nationwide Supply of Locally Made Pralsetinib as China Sales Surge

Kane Biotech Presents Data To Global Wound Care Community at WCET®–NSWOCC® 2026 Joint Congress | KNBIF Stock News

StockTitan

BlackRock, Inc.

Kane Biotech Presents Data To Global Wound Care Community at WCET®–NSWOCC® 2026 Joint Congress | KNBIF Stock News

Coloplast A/S reported a Q2 loss of 971 million Danish kroner, down from a profit of 912 million kroner last year, primarily due to a 3.03 billion kroner impairment loss related to Kerecis. Despite this, revenues rose 2% to 7.08 billion kroner, with organic growth of 6%. The company reaffirmed its FY26 outlook, projecting revenue growth of 3% and adjusted EBIT growth of around 5%. A half-year interim dividend of 5.00 kroner per share will be paid.

rttnews

SPDR S&P Health Equip

Maxwealth CSI All Share Medical Apparatus and Instruments ETF

China Merchants CSI All Share Medical Apparatus and Instruments ETF

iShares US Medical Devices

ChinaAMC CSI All Share Health Care Devices ETF

Coloplast A/S Class B

Coloplast Slips To Loss In Q2 On Hefty Charge, Revenues Rise; Confirms FY26 Outlook

Ping An CSI Medicine and Medical Device Innovation ETF(516820.SH)

Manulife Singapore to offer multi-cancer blood test starting May

01:00 ETNational Kidney Foundation Innovation Fund Invests in Biohope to Advance Personalized Medicine in Kidney Transplantation

Ab&B Bio-Tech Starts Early-Stage Trials for High-Yield RSV Vaccine as Trading Remains Suspended

STOCKS | Hong Kong's Innovative Drug Sector Declines

G Sachs Raises SBP GROUP TP to HKD8.05, Maintains Buy on Introduction of GSK Hepatitis B Drug

JPM: NRDL Adjustment to Accelerate Commercialization of Innovative Drugs; Top Picks INNOVENT BIO , WUXI APPTEC , WUXI XDC , SKB BIO

HBM Holdings Says Director Probed by CSRC, Sees No Impact on Operations

CStone Launches Nationwide Supply of Locally Made Pralsetinib as China Sales Surge

Kane Biotech Presents Data To Global Wound Care Community at WCET®–NSWOCC® 2026 Joint Congress | KNBIF Stock News

Coloplast Slips To Loss In Q2 On Hefty Charge, Revenues Rise; Confirms FY26 Outlook